• Ginsenoside Rg2 Reduces Astrocyte Inflammation and BBB Perme

  2026-07-02

  This study demonstrates that Ginsenoside Rg2 can alleviate astrocyte-mediated inflammation and strengthen blood-brain barrier (BBB) integrity in Alzheimer's disease (AD) models. The findings clarify G-Rg2's mechanism in inhibiting the TLR4/MyD88/MMP9 pathway, reducing tight junction protein loss, and providing a rationale for targeted BBB protection strategies in neurodegenerative disease research.

• Exogenous NADH Enhances Aminoglycoside Efficacy in E. tarda

  2026-07-02

  A recent study demonstrates that exogenous NADH significantly increases the bactericidal activity of aminoglycoside antibiotics against multidrug-resistant Edwardsiella tarda. By metabolically reprogramming bacterial energy pathways, this approach provides a promising strategy for overcoming antibiotic resistance in clinical and aquaculture settings.

• EGTA in Calcium Signaling Pathway Modulation: Workflow & Inn

  2026-07-01

  EGTA (egtaxic acid) empowers researchers to dissect calcium-dependent signaling with exceptional selectivity, minimizing off-target ion interference. This article translates cutting-edge findings from atherosclerosis and inflammation models into actionable protocols and troubleshooting strategies for advanced cellular research.

• RHEB Neddylation by UBE2F-SAG Axis Drives mTORC1 in Liver Ca

  2026-07-01

  This study reveals that RHEB is directly neddylated by the UBE2F-SAG axis, enhancing mTORC1 activity and promoting liver tumorigenesis. The findings elucidate a novel regulatory mechanism with clinical relevance for hepatocellular carcinoma and highlight new therapeutic targets.

• Advancing mRNA Delivery: Mechanistic Insight and Translation

  2026-06-30

  This thought-leadership article explores how innovations in dual-fluorescent, immune-evasive mRNA—specifically EZ Cap™ Cy5 EGFP mRNA (5-moUTP)—are redefining translational research strategies. By integrating mechanistic advances, competitive benchmarking, and clinical inspiration from recent nanoparticle-enabled mRNA delivery studies, we provide researchers with actionable guidance for accelerating gene delivery optimization and overcoming long-standing experimental bottlenecks.

• Berberine Hydrochloride (SKU N1368): Workflow Reliability in

  2026-06-30

  This article explores how Berberine Hydrochloride (SKU N1368) addresses core laboratory challenges in cell viability, metabolic disease, and cytotoxicity assays. Through scenario-driven Q&A, we guide researchers on protocol optimization, data interpretation, and product selection—demonstrating the reagent’s value for reproducibility and translational research.

• Bovine Insulin in Translational Research: Mechanisms & Strat

  2026-06-29

  This article demystifies the mechanistic and translational value of bovine insulin as a peptide hormone and growth supplement for cultured cells. It bridges cutting-edge insights into insulin signaling pathways, cellular metabolism, and the interplay with endoplasmic reticulum (ER) stress—offering strategic guidance for researchers advancing from bench to bedside. By drawing on new mechanistic studies, recent fibrosis research, and high-purity reagent advances, the piece positions APExBIO’s bovine insulin as a gold-standard tool while illuminating future applications and limitations.

• Topotecan Versus Classic Regimens in First-Line SCLC Therapy

  2026-06-29

  The reference study systematically evaluates topotecan-based regimens as alternatives to established first-line chemotherapy in small cell lung cancer (SCLC). Through analysis of response rates, survival outcomes, and toxicity profiles, it highlights topotecan’s potential for improved tolerability and synergy with other agents, informing future therapeutic strategies.

• Ibotenic Acid: Precision Neurotoxicity and Modeling Insights

  2026-06-28

  Explore how ibotenic acid serves as a precise NMDA receptor agonist and research tool for probing glutamatergic signaling and neurodegeneration. This article uniquely examines dose-dependent neurotoxicity findings, offering new perspectives for neuroscience workflows.

• Cyclo (-RGDfC): Applied Workflows for Tumor Targeting Resear

  2026-06-27

  Cyclo (-RGDfC) stands out as a gold-standard tumor targeting peptide for integrin αvβ3-driven cancer and angiogenesis research. Explore streamlined protocols, experimental troubleshooting, and comparative insights that empower robust, reproducible application in advanced cellular assays and targeted delivery systems.

• Ranolazine’s Metabolic Reprogramming: A Paradigm for Ischemi

  2026-06-26

  Explore how Ranolazine, an advanced anti-ischemic agent, redefines metabolic modulation in cardiac and hepatic research. This article uncovers Ranolazine’s unique dual mechanism and its implications for both mitochondrial efficiency and translational assay design.

• Calpain Overactivation Disrupts Offspring Cognition Post-Sur

  2026-06-26

  The reference study demonstrates that excessive calpain activation following maternal non-obstetric surgery during pregnancy impairs offspring cognition by disrupting hippocampal BDNF/TrkB signaling. Pharmacological inhibition with MDL 28170 partially restored neuronal integrity and cognitive performance, highlighting a mechanistic link and potential therapeutic strategy for mitigating neurodevelopmental deficits.

• Medroxyprogesterone Acetate: Precision Tools for Endometrial

  2026-06-25

  Discover the multifaceted scientific applications of Medroxyprogesterone acetate (MPA) in endometrial and renal epithelial studies. This article uniquely bridges advanced molecular mechanisms with practical assay guidance, revealing insights beyond standard protocols.

• RNA Pol II Inhibition Drives Apoptosis via Pol IIA Loss, Not

  2026-06-25

  Harper et al. (2025) reveal that cell death from RNA polymerase II (Pol II) inhibition is not a passive consequence of lost transcription but results from an active apoptotic pathway triggered by the loss of hypophosphorylated Pol IIA. This finding redefines the mechanistic landscape of apoptosis, with implications for the design of cell death assays and the interpretation of drug actions in cancer research.

• HyperScribe T7 Kit Plus: Driving Next-Gen mRNA Therapeutics

  2026-06-24

  Discover how the HyperScribe T7 High Yield RNA Synthesis Kit Plus empowers researchers to design, optimize, and scale precision mRNA synthesis for translational applications. This article explores advanced assay strategies, workflow decision-making, and the latest evidence on mRNA-based interventions.

15842 records 1/1057 page Next 12345 下5页 Last page